Amgen/ US0311621009 /
8/17/2022 3:36:14 PM | Chg. -2.61 | Volume | Bid3:36:39 PM | Ask3:36:39 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
250.54USD | -1.03% | 2,855 Turnover: 715,172.89 |
250.23Bid Size: 200 | 250.68Ask Size: 100 | 135.42 bill.USD | 2.78% | 24.48 |
GlobeNewswire
3/23
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
GlobeNewswire
3/23
OcyonBio Client Biosimilar Solutions, Inc. Initiates Registrational Clinical Trial for Its First Bio...
GlobeNewswire
3/21
Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neu...
GlobeNewswire
3/21
Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors
GlobeNewswire
3/17
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program...
GlobeNewswire
3/15
Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
GlobeNewswire
3/14
OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico
GlobeNewswire
3/9
Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors
GlobeNewswire
3/7
Dr. Gerard Blobe, M.D., Ph.D., Joins Vivacitas Oncology's Solid Tumor Medical Advisory Board
GlobeNewswire
3/3
Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8,...
GlobeNewswire
3/2
AmMax Bio Announces Positive Phase 2 Results Demonstrating Proof-of-Concept for the Novel Local Deli...
GlobeNewswire
3/1
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Busine...